BMSON Header
보건의료전문가가 아닌 경우, 한국BMS Official Site (https://www.bms.com/kr)을 방문해 주세요.
Log Out My Profile Contact Us

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Oct 26, 2021

Error
Error
Success
Success
foot note heading
BMSON Footer